Safety Study in Subjects With Leber Congenital Amaurosis
A Phase 1 Safety Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 Into the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-101]
Sponsor: Spark Therapeutics, Inc.
This PHASE1 trial investigates Leber Congenital Amaurosis and is currently completed. Spark Therapeutics, Inc. leads this study, which shows 11 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Apr 2024 [monthly]
Completed PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Aug 2019 — Dec 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Apr 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Spark Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .